<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802722</url>
  </required_header>
  <id_info>
    <org_study_id>011280</org_study_id>
    <nct_id>NCT02802722</nct_id>
  </id_info>
  <brief_title>Does Vitamin D Supplementation Enhance Resolution of Inflammation After Community-acquired Pneumonia?</brief_title>
  <acronym>ResolveD-CAP</acronym>
  <official_title>A Prospective Randomised Placebo-controlled Study of the Influence of Vitamin D Supplementation on Resolution of Inflammation Following Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous research has shown that people who have been hospitalised for pneumonia are more
      likely to die of conditions such as heart attacks, stroke and cancer in the weeks to months
      after their illness. This risk is linked to raised levels of inflammation. Laboratory
      research shows that vitamin D can help to clear inflammation. Vitamin D deficiency is very
      common in the United Kingdom. The investigators are conducting this study to find out if
      taking vitamin D can hasten long-term recovery from pneumonia by reducing inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma IL-6 concentrations</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum CRP</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total white cell count and differential white cell count in induced sputum samples</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>WBC and differential counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell phenotypes in peripheral blood</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>flow cytometry phenotypes, blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell phenotypes in induced sputum samples</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>flow cytometry phenotypes, induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pro- and anti-inflammatory mediators in peripheral blood</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>Cytokines, lipid mediators, blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pro- and anti-inflammatory mediators in induced sputum samples</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>Cytokines, lipid mediators, induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of pro- and anti-inflammatory mediators in supernatants from whole blood stimulated with antigens ex-vivo</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>Cytokines, lipid mediators, stimulated blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood transcriptional profiles</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>mRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumes of lung abnormalities on chest CT imaging</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>CT data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia symptom scores</measure>
    <time_frame>after 6 weeks of vitamin D3 supplementation</time_frame>
    <description>CAP-Sym scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 supplementation</intervention_name>
    <description>Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.</description>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <other_name>cholecalciferol</other_name>
    <other_name>colecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral blood and induced sputum sampling</intervention_name>
    <description>To attain samples for immunological testing</description>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <arm_group_label>Delayed supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chest computerised tomography (CT) scans</intervention_name>
    <description>For volumetric quantification of lung abnormalities</description>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <arm_group_label>Delayed supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Symptom questionnaire</intervention_name>
    <description>Symptom questionnaire for recent symptom history</description>
    <arm_group_label>Immediate supplementation</arm_group_label>
    <arm_group_label>Delayed supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To be dispensed using an electronic dispenser to allow real time logging of adherence.</description>
    <arm_group_label>Delayed supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults ≥50 years of age

          2. Vitamin D deficiency at entry, defined as a serum total 25(OH)D concentration &lt;50
             nmol/L

          3. Admission to hospital with an acute illness (≤21 days) consistent with
             community-acquired pneumonia - at least one symptom of a lower respiratory tract
             infection (cough, sputum production, dyspnoea, wheeze, chest discomfort or pain,
             fever) and new infiltrate on chest radiograph

          4. Adequate mental capacity to give informed consent for participation in the study and
             gives written informed consent

        Exclusion Criteria:

          1. Currently taking any vitamin D supplementation

          2. Known HIV infection, other condition causing immunosuppression, current
             immunosuppressive therapy or systemic corticosteroids

          3. Known malignancy not in remission for &gt;3 years or terminal illness with prognosis
             &lt;1year

          4. History of smoking within the previous 1 year

          5. Known or suspected diagnosis of chronic obstructive pulmonary disease (COPD)

          6. Previous hospitalisation within 10 days of admission

          7. Aspiration pneumonia diagnosed by the clinical team

          8. Known diagnosis of cystic fibrosis, bronchiectasis or interstitial lung disease at
             screening

          9. Complications of pneumonia such as empyema or lung abscess at entry

         10. Recent acute coronary syndrome within the previous 1 month

         11. Long term oxygen therapy, chronic mechanical ventilation dependency or other
             contraindication to sputum induction

         12. Serum corrected calcium concentration &gt;2.65 mmol/L at entry

         13. Chronic kidney disease stage 4-5 (estimated glomerular filtration rate &lt;30ml/min) on
             an existing blood sample from the current hospital admission

         14. Known clinical diagnosis of liver failure

         15. Known or suspected diagnosis of active pulmonary tuberculosis

         16. Known diagnosis of primary hyperparathyroidism

         17. Known diagnosis of sarcoidosis

         18. Known diagnosis of nephrolithiasis

         19. Taking carbamazepine, phenytoin, phenobarbital, primidone, cardiac glycosides or
             benzothiadiazines with concomitant calcium supplementation at entry

         20. Known allergy to vitamin D or its excipients

         21. Currently taking part in another research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Martineau, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Queen Mary University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia D Yeap, MBBS</last_name>
    <phone>(44)7810715924</phone>
    <email>a.d.yeap@qmul.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Yeap, MBBS</last_name>
      <phone>+447810715924</phone>
      <email>a.d.yeap@qmul.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Alicia Yeap, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC; GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1242-7. doi: 10.1164/rccm.200712-1777OC. Epub 2008 Mar 27.</citation>
    <PMID>18369199</PMID>
  </reference>
  <reference>
    <citation>Remmelts HH, van de Garde EM, Meijvis SC, Peelen EL, Damoiseaux JG, Grutters JC, Biesma DH, Bos WJ, Rijkers GT. Addition of vitamin D status to prognostic scores improves the prediction of outcome in community-acquired pneumonia. Clin Infect Dis. 2012 Dec;55(11):1488-94. doi: 10.1093/cid/cis751. Epub 2012 Aug 31.</citation>
    <PMID>22942205</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>convalescence</keyword>
  <keyword>inflammation</keyword>
  <keyword>resolution</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

